Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZSP, Genzyme Surgical Products -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (51)	2/18/2000 2:17:00 PM
From: jeffbas	Respond to of 55

"A price in the mid-80's" for who?

To: LLCF who wrote (51)	2/19/2000 1:43:00 AM
From: Torben Noerup Nielsen	Respond to of 55

David, I'd consider selling my GLIA in the low 80's :-) Seriously, I think it's well on its way there. Give it a couple of years and you're likely to have ADCON-L, ADCON-P, ADCON-A, ADCON-T/N and Perceptin on the market. Plus possibly one or two others close to it. I see no reason why Gliatech can't do it. They're going to have the revenue from the ADCON products to fuel the development of the biotech side of the house. They've got nothing else to use it on. What I like about Gliatech as opposed to other medical supplies products is that they're sticking to a very well defined core area of competence: glial cells. As I recall, all the ADCON products are outgrowths of research in that area. So there's focus. To me, a well-defined focus is more important than just about anything else. Thanks, Torben